191 related articles for article (PubMed ID: 12091344)
21. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites.
Gale AJ; Heeb MJ; Griffin JH
Blood; 2000 Jul; 96(2):585-93. PubMed ID: 10887122
[TBL] [Abstract][Full Text] [Related]
22. Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va.
Tran S; Norstrøm E; Dahlbäck B
J Biol Chem; 2008 Mar; 283(11):6648-55. PubMed ID: 18198180
[TBL] [Abstract][Full Text] [Related]
23. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals.
Camire RM; Kalafatis M; Cushman M; Tracy RP; Mann KG; Tracy PB
J Biol Chem; 1995 Sep; 270(35):20794-800. PubMed ID: 7657663
[TBL] [Abstract][Full Text] [Related]
24. The mechanism of inactivation of human factor V and human factor Va by activated protein C.
Kalafatis M; Rand MD; Mann KG
J Biol Chem; 1994 Dec; 269(50):31869-80. PubMed ID: 7989361
[TBL] [Abstract][Full Text] [Related]
25. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V.
Lu D; Kalafatis M; Mann KG; Long GL
Blood; 1996 Jun; 87(11):4708-17. PubMed ID: 8639840
[TBL] [Abstract][Full Text] [Related]
26. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.
Noordermeer T; Chemlal S; Jansma JJ; van der Vegte V; Schutgens REG; Limper M; de Groot PG; Meijers JCM; Urbanus RT
J Thromb Haemost; 2023 Sep; 21(9):2509-2518. PubMed ID: 37290588
[TBL] [Abstract][Full Text] [Related]
27. Regulation of factor V by the anticoagulant protease activated protein C: Influence of the B-domain and TFPIα.
Ayombil F; Petrillo T; Kim H; Camire RM
J Biol Chem; 2022 Nov; 298(11):102558. PubMed ID: 36183835
[TBL] [Abstract][Full Text] [Related]
28. Activated protein C resistance: molecular mechanisms.
Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
[TBL] [Abstract][Full Text] [Related]
29. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
30. The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.
Gierula M; Salles-Crawley II; Santamaria S; Teraz-Orosz A; Crawley JTB; Lane DA; Ahnström J
J Thromb Haemost; 2019 Dec; 17(12):2056-2068. PubMed ID: 31364267
[TBL] [Abstract][Full Text] [Related]
31. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
[TBL] [Abstract][Full Text] [Related]
32. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
[TBL] [Abstract][Full Text] [Related]
33. Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations.
Shimonishi N; Ogiwara K; Yoshida J; Horie K; Nakajima Y; Furukawa S; Takeyama M; Nogami K
Blood Adv; 2023 Jun; 7(12):2831-2842. PubMed ID: 36780344
[TBL] [Abstract][Full Text] [Related]
34. The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function.
Nyberg P; Dahlbäck B; García de Frutos P
FEBS Lett; 1998 Aug; 433(1-2):28-32. PubMed ID: 9738926
[TBL] [Abstract][Full Text] [Related]
35. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.
Nicolaes GA; Tans G; Thomassen MC; Hemker HC; Pabinger I; Varadi K; Schwarz HP; Rosing J
J Biol Chem; 1995 Sep; 270(36):21158-66. PubMed ID: 7673148
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the molecular defect in factor VR506Q.
Kalafatis M; Bertina RM; Rand MD; Mann KG
J Biol Chem; 1995 Feb; 270(8):4053-7. PubMed ID: 7876154
[TBL] [Abstract][Full Text] [Related]
37. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
[TBL] [Abstract][Full Text] [Related]
38. APC resistance: biological basis and acquired influences.
Castoldi E; Rosing J
J Thromb Haemost; 2010 Mar; 8(3):445-53. PubMed ID: 20002539
[TBL] [Abstract][Full Text] [Related]
39. Protein S Thr103Asn mutation associated with type II deficiency reproduced in vitro and functionally characterised.
Giri TK; García de Frutos P; Dahlbäck B
Thromb Haemost; 2000 Sep; 84(3):413-9. PubMed ID: 11019964
[TBL] [Abstract][Full Text] [Related]
40. The anticoagulant function of coagulation factor V.
Cramer TJ; Gale AJ
Thromb Haemost; 2012 Jan; 107(1):15-21. PubMed ID: 22116556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
